[SCHEDULE 13G/A] Reviva Pharmaceuticals Holdings, Inc. SEC Filing
Reviva Pharmaceuticals Holdings, Inc. Schedule 13G/A discloses that Tang-related reporting persons jointly beneficially own 3,399,975 shares of the issuer's common stock, representing 4.8% of the class on a basis that includes those shares as currently issuable upon exercise of warrants. All reported shares are currently issuable upon exercise of warrants described in the issuer's prospectus; the filing specifies that Tang Capital Partners, LP holds 4,533,300 Investor Warrants exercisable for 0.75 of a share each and subject to ownership limits that cap post-exercise ownership at 9.99% (with a potential increase to up to 19.99% after notice). The reporting persons indicate shared voting and dispositive power over the reported shares and state the position is not held to change or influence control of the issuer.
Reviva Pharmaceuticals Holdings, Inc. nella Schedule 13G/A dichiara che le persone di segnalazione collegate a Tang detengono congiuntamente la titolarit脿 beneficiaria di 3.399.975 azioni del capitale sociale ordinario dell'emittente, corrispondenti al 4,8% della classe su base che include le azioni attualmente emettibili mediante esercizio di warrant. Tutte le azioni riportate sono attualmente emettibili mediante esercizio dei warrant descritti nel prospetto dell'emittente; il deposito specifica che Tang Capital Partners, LP detiene 4.533.300 Investor Warrants esercitabili per 0,75 azione ciascuno e soggetti a limiti di propriet脿 che plafonano la partecipazione post-esercizio al 9,99% (con possibile aumento fino al 19,99% previa comunicazione). Le persone di segnalazione dichiarano di avere potere condiviso di voto e dispositiva sulle azioni riportate e affermano che la posizione non 猫 detenuta per modificare o influenzare il controllo dell'emittente.
Reviva Pharmaceuticals Holdings, Inc. en la Schedule 13G/A revela que las personas informantes relacionadas con Tang poseen de forma conjunta la propiedad beneficiaria de 3.399.975 acciones del capital social com煤n de la emisora, lo que representa el 4,8% de la clase sobre una base que incluye las acciones actualmente emitibles mediante el ejercicio de warrants. Todas las acciones informadas son actualmente emitibles mediante el ejercicio de los warrants descritos en el prospecto de la emisora; la presentaci贸n especifica que Tang Capital Partners, LP posee 4.533.300 Investor Warrants ejercitables por 0,75 de una acci贸n cada uno y sujetos a l铆mites de propiedad que restringen la participaci贸n tras el ejercicio al 9,99% (con un posible aumento hasta el 19,99% tras notificaci贸n). Las personas informantes indican que tienen poder compartido de voto y disposici贸n sobre las acciones reportadas y declaran que la posici贸n no se mantiene con el fin de cambiar o influir en el control de la emisora.
Reviva Pharmaceuticals Holdings, Inc.鞚� Schedule 13G/A電� Tang 甏�霠� 氤搓碃鞛愱皜 氚滍枆須岇偓鞚� 氤错喌欤� 3,399,975欤�毳� 瓿惦彊鞙茧 鞁れ鞝� 靻岇湢頃橁碃 鞛堨潓鞚� 瓿奠嫓頃橂┌, 鞚措姅 鞗岆煱韸� 頄夓偓搿� 順勳灛 氚滍枆 臧�電ロ暅 欤检嫕鞚� 韽暔頃� 旮办鞙茧 頃措嫻 膦呺鞚� 4.8%鞐� 頃措嫻頃╇媹雼�. 氤搓碃霅� 氇摖 欤检嫕鞚� 氚滍枆須岇偓 鞎堧偞靹滌棎 靹る獏霅� 鞗岆煱韸胳潣 頄夓偓搿� 順勳灛 氚滍枆 臧�電ロ晿瓿�; 鞝滌稖靹滊電� Tang Capital Partners, LP臧� 臧侁皝 0.75欤茧 頄夓偓 臧�電ロ暅 4,533,300臧滌潣 Investor Warrants毳� 氤挫湢頃橁碃 鞛堨溂氅�, 頄夓偓 頉� 靻岇湢歆�攵勳潉 9.99%搿� 鞝滍暅頃橂姅 靻岇湢 頃滊弰(韱奠 頉� 斓滊寑 19.99%搿� 靸來枼 臧�電�)鞚� 鞝侅毄鞚� 氚涬姅雼り碃 氇呾嫓頃╇媹雼�. 氤搓碃鞛愲摛鞚� 氤搓碃霅� 欤检嫕鞐� 雽�頃� 瓿惦彊鞚� 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨溂氅� 鞚� 歆�攵勳澊 氚滍枆須岇偓鞚� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暅 氇╈爜鞚� 鞎勲媹霛缄碃 氚濏灆雼堧嫟.
Reviva Pharmaceuticals Holdings, Inc. dans la Schedule 13G/A r茅v猫le que les personnes d茅clarantes li茅es 脿 Tang d茅tiennent conjointement la propri茅t茅 b茅n茅ficiaire de 3 399 975 actions des actions ordinaires de l'茅metteur, repr茅sentant 4,8% de la cat茅gorie sur la base incluant les actions actuellement 茅mettables par exercice de warrants. Toutes les actions d茅clar茅es sont actuellement 茅mettables par exercice des warrants d茅crits dans le prospectus de l'茅metteur ; le d茅p么t pr茅cise que Tang Capital Partners, LP d茅tient 4 533 300 Investor Warrants exer莽ables pour 0,75 d'une action chacun et soumis 脿 des limites de d茅tention plafonnant la participation apr猫s exercice 脿 9,99% (avec une augmentation possible jusqu'脿 19,99% apr猫s notification). Les personnes d茅clarantes indiquent d茅tenir le pouvoir conjoint de vote et de disposition sur les actions d茅clar茅es et d茅clarent que la position n'est pas destin茅e 脿 modifier ou influencer le contr么le de l'茅metteur.
Reviva Pharmaceuticals Holdings, Inc. gibt in der Schedule 13G/A an, dass die Tang鈥慴ezogenen meldepflichtigen Personen gemeinsam das wirtschaftliche Eigentum an 3.399.975 Aktien der Stammaktien des Emittenten halten, was 4,8% der Klasse auf der Basis einschlie脽t, dass diese Aktien derzeit durch Aus眉bung von Warrants ausgegeben werden k枚nnen. Alle gemeldeten Aktien sind derzeit durch Aus眉bung der im Prospekt des Emittenten beschriebenen Warrants emittierbar; die Einreichung legt fest, dass Tang Capital Partners, LP 4.533.300 Investor Warrants h盲lt, die jeweils f眉r 0,75 einer Aktie aus眉bbar sind und Eigentumsgrenzen unterliegen, die die Beteiligung nach Aus眉bung auf 9,99% begrenzen (mit m枚glicher Erh枚hung auf bis zu 19,99% nach Mitteilung). Die meldepflichtigen Personen geben an, 眉ber die gemeldeten Aktien gemeinsame Stimm- und Verf眉gungsmacht zu verf眉gen und erkl盲ren, dass die Position nicht dazu gehalten ist, die Kontrolle 眉ber den Emittenten zu 盲ndern oder zu beeinflussen.
- Transparent disclosure of beneficial ownership and voting/dispositive arrangements among Tang entities
- Ownership below 5% (4.8%), consistent with non-control passive reporting under Schedule 13G/A
- Clear contractual limits on warrant exercise that cap post-exercise ownership at 9.99% (with a potential increase to 19.99% after notice)
- All reported shares are issuable upon exercise of warrants, representing potential dilution if exercised
- Investor Warrants (4,533,300 held by TCP) convert at 0.75 share each, complicating straightforward share-count dilution calculations
Insights
TL;DR: Tang parties hold 4.8% beneficial ownership via warrants; position is below 5% and disclosed as not intended to influence control.
The filing shows an economically meaningful but sub-5% stake represented entirely by currently exercisable warrants totaling 3,399,975 shares on an as-exercised basis. Because the position is characterized as shared power among affiliated entities and limited by explicit ownership caps, this disclosure signals a strategic, monitored stake rather than an outright equity accumulation. The presence of Investor Warrants exercisable for 0.75 shares each and the stated ownership limits are material for modeling potential dilution and future voting dynamics, but the current reported percentage remains below thresholds typically associated with control or activist intent.
TL;DR: Reporting persons disclose shared voting/dispositive power and ownership limits; filing meets Schedule 13G/A transparency norms.
The statement clarifies beneficial ownership, allocation of voting and dispositive authority among Tang entities, and contractual limits on post-exercise ownership. These specifics are important for governance analysis because they define the scope of influence the group can exert and set automatic constraints on aggregate ownership following warrant exercises. The certification asserts the position is not held to change control, aligning the filing with passive-investor reporting under Schedule 13G/A rather than an active control-seeking disclosure.
Reviva Pharmaceuticals Holdings, Inc. nella Schedule 13G/A dichiara che le persone di segnalazione collegate a Tang detengono congiuntamente la titolarit脿 beneficiaria di 3.399.975 azioni del capitale sociale ordinario dell'emittente, corrispondenti al 4,8% della classe su base che include le azioni attualmente emettibili mediante esercizio di warrant. Tutte le azioni riportate sono attualmente emettibili mediante esercizio dei warrant descritti nel prospetto dell'emittente; il deposito specifica che Tang Capital Partners, LP detiene 4.533.300 Investor Warrants esercitabili per 0,75 azione ciascuno e soggetti a limiti di propriet脿 che plafonano la partecipazione post-esercizio al 9,99% (con possibile aumento fino al 19,99% previa comunicazione). Le persone di segnalazione dichiarano di avere potere condiviso di voto e dispositiva sulle azioni riportate e affermano che la posizione non 猫 detenuta per modificare o influenzare il controllo dell'emittente.
Reviva Pharmaceuticals Holdings, Inc. en la Schedule 13G/A revela que las personas informantes relacionadas con Tang poseen de forma conjunta la propiedad beneficiaria de 3.399.975 acciones del capital social com煤n de la emisora, lo que representa el 4,8% de la clase sobre una base que incluye las acciones actualmente emitibles mediante el ejercicio de warrants. Todas las acciones informadas son actualmente emitibles mediante el ejercicio de los warrants descritos en el prospecto de la emisora; la presentaci贸n especifica que Tang Capital Partners, LP posee 4.533.300 Investor Warrants ejercitables por 0,75 de una acci贸n cada uno y sujetos a l铆mites de propiedad que restringen la participaci贸n tras el ejercicio al 9,99% (con un posible aumento hasta el 19,99% tras notificaci贸n). Las personas informantes indican que tienen poder compartido de voto y disposici贸n sobre las acciones reportadas y declaran que la posici贸n no se mantiene con el fin de cambiar o influir en el control de la emisora.
Reviva Pharmaceuticals Holdings, Inc.鞚� Schedule 13G/A電� Tang 甏�霠� 氤搓碃鞛愱皜 氚滍枆須岇偓鞚� 氤错喌欤� 3,399,975欤�毳� 瓿惦彊鞙茧 鞁れ鞝� 靻岇湢頃橁碃 鞛堨潓鞚� 瓿奠嫓頃橂┌, 鞚措姅 鞗岆煱韸� 頄夓偓搿� 順勳灛 氚滍枆 臧�電ロ暅 欤检嫕鞚� 韽暔頃� 旮办鞙茧 頃措嫻 膦呺鞚� 4.8%鞐� 頃措嫻頃╇媹雼�. 氤搓碃霅� 氇摖 欤检嫕鞚� 氚滍枆須岇偓 鞎堧偞靹滌棎 靹る獏霅� 鞗岆煱韸胳潣 頄夓偓搿� 順勳灛 氚滍枆 臧�電ロ晿瓿�; 鞝滌稖靹滊電� Tang Capital Partners, LP臧� 臧侁皝 0.75欤茧 頄夓偓 臧�電ロ暅 4,533,300臧滌潣 Investor Warrants毳� 氤挫湢頃橁碃 鞛堨溂氅�, 頄夓偓 頉� 靻岇湢歆�攵勳潉 9.99%搿� 鞝滍暅頃橂姅 靻岇湢 頃滊弰(韱奠 頉� 斓滊寑 19.99%搿� 靸來枼 臧�電�)鞚� 鞝侅毄鞚� 氚涬姅雼り碃 氇呾嫓頃╇媹雼�. 氤搓碃鞛愲摛鞚� 氤搓碃霅� 欤检嫕鞐� 雽�頃� 瓿惦彊鞚� 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨溂氅� 鞚� 歆�攵勳澊 氚滍枆須岇偓鞚� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暅 氇╈爜鞚� 鞎勲媹霛缄碃 氚濏灆雼堧嫟.
Reviva Pharmaceuticals Holdings, Inc. dans la Schedule 13G/A r茅v猫le que les personnes d茅clarantes li茅es 脿 Tang d茅tiennent conjointement la propri茅t茅 b茅n茅ficiaire de 3 399 975 actions des actions ordinaires de l'茅metteur, repr茅sentant 4,8% de la cat茅gorie sur la base incluant les actions actuellement 茅mettables par exercice de warrants. Toutes les actions d茅clar茅es sont actuellement 茅mettables par exercice des warrants d茅crits dans le prospectus de l'茅metteur ; le d茅p么t pr茅cise que Tang Capital Partners, LP d茅tient 4 533 300 Investor Warrants exer莽ables pour 0,75 d'une action chacun et soumis 脿 des limites de d茅tention plafonnant la participation apr猫s exercice 脿 9,99% (avec une augmentation possible jusqu'脿 19,99% apr猫s notification). Les personnes d茅clarantes indiquent d茅tenir le pouvoir conjoint de vote et de disposition sur les actions d茅clar茅es et d茅clarent que la position n'est pas destin茅e 脿 modifier ou influencer le contr么le de l'茅metteur.
Reviva Pharmaceuticals Holdings, Inc. gibt in der Schedule 13G/A an, dass die Tang鈥慴ezogenen meldepflichtigen Personen gemeinsam das wirtschaftliche Eigentum an 3.399.975 Aktien der Stammaktien des Emittenten halten, was 4,8% der Klasse auf der Basis einschlie脽t, dass diese Aktien derzeit durch Aus眉bung von Warrants ausgegeben werden k枚nnen. Alle gemeldeten Aktien sind derzeit durch Aus眉bung der im Prospekt des Emittenten beschriebenen Warrants emittierbar; die Einreichung legt fest, dass Tang Capital Partners, LP 4.533.300 Investor Warrants h盲lt, die jeweils f眉r 0,75 einer Aktie aus眉bbar sind und Eigentumsgrenzen unterliegen, die die Beteiligung nach Aus眉bung auf 9,99% begrenzen (mit m枚glicher Erh枚hung auf bis zu 19,99% nach Mitteilung). Die meldepflichtigen Personen geben an, 眉ber die gemeldeten Aktien gemeinsame Stimm- und Verf眉gungsmacht zu verf眉gen und erkl盲ren, dass die Position nicht dazu gehalten ist, die Kontrolle 眉ber den Emittenten zu 盲ndern oder zu beeinflussen.
FAQ
How many Reviva (RVPH) shares do the Tang reporting persons beneficially own?
Are the reported RVPH shares currently outstanding or issuable?
What warrants does Tang Capital Partners (TCP) hold related to RVPH?
Does the filing indicate the Tang group seeks to influence control of RVPH?
Who shares voting and dispositive power over the reported RVPH shares?
Are there contractual limits on exercising the warrants?
